5′-End Engineering of CRISPR/Cas12a Activators: A Versatile Platform for Multiple Biomarker Analysis and Clinical Cancer Tissue Identification
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.5c03168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Jia-Yi Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sc…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Biosensing Techniques, Biomarkers, Tumor, Carcinoma, Renal Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Tianjin Municipality, Science Fund for Distinguished Young Scholars of Tianjin Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
The CRISPR/Cas12a system has emerged as a powerful tool for biosensing due to its unique trans-cleavage activity. However, the fundamental mechanisms governing its activation remain inadequately understood, limiting the design flexibility and application scope of CRISPR/Cas12a-based biosensors. In this study, we investigated the activation behavior of CRISPR/Cas12a, focusing on the 5'-end engineering of the activator strand. We discovered that the activation of CRISPR/Cas12a can be significantly suppressed by incorporating a rigid intramolecular hairpin or intermolecular duplex at the 5'-end of the activator strand designed using our discovered RESET effect. Leveraging this finding, we developed a series of CRISPR/Cas12a-based biosensors capable of sensitive and selective detection, as well as live-cell imaging, for various biomarkers including microRNAs, biological small molecules, enzymes, and reactive oxygen species. Notably, the biosensor designed for miR-210, a biomarker for renal cell carcinoma (RCC), demonstrated exceptional performance in distinguishing between clinical RCC tissues and adjacent healthy tissues, highlighting its potential for cancer diagnosis, prognosis, and intraoperative decision-making. This study not only deepens the understanding of CRISPR/Cas12a activation mechanisms but also provides a versatile platform for developing advanced biosensors in molecular diagnostics and therapeutic monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, Nankai University, Tianjin 300071, P. R.…
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, P. R. China.
ORCID-Profile: Gui-Mei Han, De-Ming Kong
Förderung
- Natural Science Foundation of Tianjin Municipality
- Science Fund for Distinguished Young Scholars of Tianjin Municipality
- National Natural Science Foundation of China
- Talent Cultivation Project of Tianjin Institute of Urology
- Tianjin Health High-level Talent Cultivation Project
Zitieren
APA
Shi, J. Y., Li, Z. W., Yao, Z. L., Han, G. M., Li, M. Y., Cai, Q. L., & Kong, D. M. (2025). 5′-End Engineering of CRISPR/Cas12a Activators: A Versatile Platform for Multiple Biomarker Analysis and Clinical Cancer Tissue Identification. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.5c03168
Vancouver
Shi JY, Li ZW, Yao ZL, Han GM, Li MY, Cai QL, et al. 5′-End Engineering of CRISPR/Cas12a Activators: A Versatile Platform for Multiple Biomarker Analysis and Clinical Cancer Tissue Identification. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.5c03168
BibTeX
@article{Shi2025,
author = {Shi, Jia-Yi and Li, Zi-Wen and Yao, Zhi-Li and Han, Gui-Mei and Li, Man-Ying and Cai, Qi-Liang and Kong, De-Ming},
title = {5′-End Engineering of CRISPR/Cas12a Activators: A Versatile Platform for Multiple Biomarker Analysis and Clinical Cancer Tissue Identification},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.5c03168}
}
EUVIMED